The company posted a GAAP-based net loss of $4 billion for the year.
BiomX is planning future treatments for Crohn's Disease, colitis, and even cancer.
The Teva share price reached its peak in July 2015, when it was trading at over $70.
RM Global Israel's Yaron Breski: Anyone not involved in breakthrough companies from the beginning won't have a foothold in the next scientific revolution.
IATI: The trend in Israel is away from medical devices and towards digital medicine.
Reports in the Hungarian media say that Teva plans to sell or close down one of its Hungarian plants by the end of 2018.
Since August, the number of employees at Teva has dropped by 5,000, including 1,700 since the beginning of this year.
The round was led by OrbiMed, Johnson & Johnson Innovation, and Takeda Ventures.
Body Vision integrates a CT scan and X-ray in order to remove very small lung tumors that might develop into lung cancer.
"Globes" profiles the 10 Israeli startups in the Reboot Forum 2017’s Leading Healthcare Initiative, presenting innovations based mainly on big data analytics.